Phase IIstudy of biweekly FOLFIRI+cetuximab treatment for unresectable KRAS-wild type colorectal cancer
Phase 2
- Conditions
- unresectable colorectal cancer
- Registration Number
- JPRN-UMIN000011363
- Lead Sponsor
- Dept of Surgical Oncology Osaka City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
severe dysfunction of bone marrow, liver, renal, and cardiac function no prior radiotherapy, chemotherapy or any molecular targeting therapy for rectal cancer; no other co-existing malignancy or malignancy within the last five years prior to enrollment no severe concurrent medical or psychiatric illness no a known hypersensitivity to the study drugs none of the patients were pregnant or lactating.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Disease free survival Overall survival